Amgen And Cytokinetics Partner On Novel Heart Failure Treatments
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal could be worth more than $725 million.
You may also be interested in...
BIO CEO & Investor Conference In Brief
CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said
BIO CEO & Investor Conference In Brief
CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said
Cytokinetics’ First Phase IIa Data Strong For Heart Failure Drug
Success takes the firm closer to Amgen payday.